ITIH4: A New Potential Biomarker of “Toxin Syndrome” in Coronary Heart Disease Patient Identified with Proteomic Method
Table 2
Comparison of before and after treatment in group A ().
Mass (Da)
Ave ± StdDev (A-Q)
Ave ± StdDev (A-H)
1076.12
3.77 ± 2.35
2.54 ± 1.24
0.016099
1136.37
7.25 ± 3.12
5.42 ± 2.08
0.008065
1205.62
9 ± 3.32
6.92 ± 4.43
0.018784
1329.42
14.44 ± 7.31
10.26 ± 4.92
0.000268
1348.81
10.41 ± 4.08
7.09 ± 2.89
0.000806
1464.89
24.93 ± 13.64
13.52 ± 6.44
0.000293
1519.06
18.49 ± 8.17
11.39 ± 5.92
0.000111
1544.61
30.66 ± 17.33
19.41 ± 16.3
0.011662
1616.74
33.35 ± 22.17
18.7 ± 9.09
0.002143
2209.31
37.24 ± 18.84
25.45 ± 17.84
0.01935
2279.51
50.15 ± 17.26
40.99 ± 14.08
0.018232
2644.01
30.08 ± 20.39
22.42 ± 14.8
0.000347
2660.01
288.15 ± 231.67
206.03 ± 161.86
0.003587
2862.02
77.55 ± 78.74
45.15 ± 29.33
0.00951
3261.70
125.1 ± 63.45
159.89 ± 62.44
0.043161
3277.49
45.57 ± 23.64
59.7 ± 29.1
0.015557
4053.87
71.26 ± 38.16
95.63 ± 53.55
0.047052
4710.25
15.53 ± 5.5
12.84 ± 4.04
0.028146
4936.10
17.25 ± 15.28
9.77 ± 2.99
0.015955
4964.02
147.4 ± 184.34
59.95 ± 34.25
0.019728
5807.76
52.08 ± 23.63
70.92 ± 24.68
0.010841
5822.51
22.33 ± 13.95
31.77 ± 10.34
0.007368
5904.69
881.7 ± 598.83
1266.04 ± 415.59
0.00471
6049.22
27.36 ± 10.77
32.41 ± 10.1
0.023583
Note: paired sample test was used, 2-tailed, and was considered significant; Ave: peak area/intensity average; StdDev: standard deviation of the peak area/intensity average; A-Q: before treatment in group A; A-H: after treatment in group A.
